Liquidia Corporation

MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its third quarter 2026 financial results on Tuesday, November 10, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.

LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.

Liquidia Corporation (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New York, New York--(Newsfile Corp. - October 21, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened?

Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.

Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.

A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.

U.S. stocks were mostly lower, with the Nasdaq Composite falling around 200 points on Wednesday.

Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.

MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it has entered into a global settlement agreement with United Therapeutics Corporation (Nasdaq: UTHR) that resolves all pending litigation between the companies. Importantly, YUTREPIA® (treprostinil) inhalation powder will remain available t…

Liquidia Corporation (LQDA) Securities Investigation Notice - Levi and KorsinskyPR NewswireNEW YORK, Oct. 12, 2026Liquidia shareholders took a roughly 57% loss af

Liquidia shareholders took a roughly 57% loss after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation concerns whether investors had an accurate picture of that litigation risk before the losses occurred.

Liquidia Corporation (NASDAQ: LQDA - Get Free Report)'s stock price gapped up prior to trading on Monday. The stock had previously closed at $27.38, but opened at $29.27. Liquidia shares last traded at $29.0220, with a volume of 955,427 shares. Analyst Upgrades and Downgrades A number of equities research analysts have commented on the company. Wedbush

A reported 57% plunge followed a court finding against Yutrepia. That market reaction is now the focus of a Levi & Korsinsky investigation into potential securities law violations A reported 57% plunge followed a court finding against Yutrepia. That market reaction is now the focus of a Levi & Korsinsky investigation into potential securities law violations

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv

LOS ANGELES--(BUSINESS WIRE)---- $LQDA--LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Liquidia (LQDA) To Contact Him Directly To Discuss Their Options

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Liquidia securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investi…

A court finding that Yutrepia infringed two valid claims of United Therapeutics' '327 patent has put the drug's PH-ILD indication and broader availability at risk. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of Liquidia investors who lost money.

LQDA shareholders who lost money after a court found that Yutrepia infringed two valid United Therapeutics patent claims may have the right to seek recovery. The investigation includes Liquidia's forecast of more than $1 billion in 2027 net revenue.